HIGHLIGHTS
- who: Conor Hennessy from the University of Algarve, Portugal University of Pittsburgh, United States have published the article: Barriers to Treg therapy in Europe: From production to regulation, in the Journal: (JOURNAL)
- future: Any investigational medicinal product (IMP) that is undergoing a first in human trial is also required to submit an investigational medicinal products dossier (IMPD). Currently in the UK and France these therapies are being reimbursed using a Coverage with Evidence development scheme (CED) in which longer term outcomes of treatment will be used to inform future pricing.
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.